Comprehensive Solutions for Long COVID: Advanced Diagnostic Insights

Long COVID, also known as post-COVID syndrome, presents significant challenges due to its persistent symptoms—such as fatigue, cognitive impairment, and respiratory difficulties—that can linger long after the initial infection has resolved. Understanding this complex condition requires advanced diagnostic tools to uncover its underlying biological mechanisms.

At Eve Technologies, our CLIA-certified Long COVID Vascular Health Panel is designed specifically for patient diagnostics, offering healthcare providers a high-precision solution to assess key biomarkers associated with it. This specialized tool provides critical insights that aid in accurate diagnosis and personalized management, ensuring patients receive the most effective care.

The Science Behind Long COVID

Understanding post-COVID syndrome requires a deep exploration of its intricate pathology. Recent research has shed light on various aspects of the condition, emphasizing the need for advanced diagnostic tools.

A notable study published in Nature investigated the impact of Coronavirus Aftereefects on vascular health, revealing that immune profiling can uncover biomarkers associated with vascular dysfunction, inflammation, and coagulation. This research highlights how detailed diagnostic methods are crucial for unraveling the complex mechanisms underlying Long COVID [1].

Further exploration into the long-term effects of COVID-19 on vascular health was conducted in research featured on ScienceDirect. Studies such as “Immunological Responses and  Biomarkers of COVID-19” and “Long-Term Vascular Complications of COVID-19” provided significant insights into how specific biomarkers can indicate persistent symptoms and track disease progression [2]. These findings underscore the importance of robust diagnostic approaches in monitoring and understanding Long COVID.

In addition, another study focusing on immune profiling observed notable changes in immune cell populations and hormone levels among Post-COVID Syndrome patients. Increased levels of non-conventional monocytes and altered T cell distributions were detected, showcasing the value of advanced diagnostic methods in identifying immunological changes related to ongoing COVID-19 Complications [3].

These studies collectively highlight the complexity of Long COVID and the critical role that advanced diagnostics play in understanding and managing this challenging condition.

Introducing Our CLIA Certified Long COVID Panel

Eve Technologies’ Long COVID Vascular Health Panel is specially designed and certified under CLIA for clinical use. Our panel offers a comprehensive analysis of biomarkers associated with Long COVID vascular health, delivering high precision results that meet stringent CLIA standards. The panel includes the following biomarkers:

• ADAMTS13: Regulates blood clotting and vascular integrity.
• Angiopoietin-2: Involved in angiogenesis and vascular remodeling.
• BMP-9: Associated with vascular health and bone formation.
• D-Dimer: Marker of coagulation and fibrinolysis.
• Endoglin: Co-receptor involved in angiogenesis and vascular development.
• Endothelin-1: Regulates vascular tone and blood pressure.
• FGF-1 (Fibroblast Growth Factor-1): Important for cell growth and tissue repair.
• Follistatin: Modulates inflammation and tissue remodeling.
• HB-EGF (Heparin-Binding Epidermal Growth Factor): Involved in cell proliferation and repair.
• HGF (Hepatocyte Growth Factor): Plays a role in tissue regeneration and repair.
• Leptin: Regulates energy balance and inflammation.
• PLGF (Placental Growth Factor): Associated with angiogenesis and vascular health.
• SAA (Serum Amyloid A): Acute-phase protein involved in inflammation.
• sICAM-1 (Soluble Intercellular Adhesion Molecule-1): Reflects endothelial activation and inflammation.
• sP-Selectin (Soluble P-Selectin): Marker of platelet activation and endothelial dysfunction.
• sVCAM-1 (Soluble Vascular Cell Adhesion Molecule-1): Indicates vascular inflammation and endothelial activation.
• VEGF-C and VEGF-D: Growth factors involved in lymphangiogenesis and vascular development.

This panel investigates crucial aspects of Long COVID Vascular Health, including vascular and endothelial integrity, coagulation, and inflammation. Reference intervals are available for PLASMA-EDTA samples, ensuring accurate and reliable results. Additionally, our results format includes report comments to assist with the interpretation of findings.

Why Choose Our Long COVID Panel?

Our panel offers several key benefits:

• Comprehensive Biomarker Coverage: Provides a detailed analysis of biomarkers relevant to Ongoing COVID-19 Complications, ensuring a thorough diagnostic approach.
• CLIA Certified for Clinical Use: As a CLIA certified laboratory, we provide a panel that meets the highest standards of accuracy and reliability for clinical diagnostics.
• High Precision Results: Our assays deliver high precision results, essential for accurate diagnosis and effective management of Long COVID.
• Affordable Assay Services: We offer some of the most affordable assay services available, making advanced diagnostics accessible for clinical and research applications.

A Valuable Tool for Healthcare Providers

Our panel stands out as a unique and specialized diagnostic tool, specially designed and CLIA certified for clinical use. It offers a cutting-edge solution for assessing Long COVID vascular health, providing healthcare providers with exceptional accuracy and high precision results. This panel is a significant advancement in understanding  and managing Post-COVID Syndrome, ensuring that patients receive the most comprehensive and reliable diagnostic insights available.

Contributing to Long COVID Research and Patient Care

For researchers seeking flexible diagnostic options, we invite you to explore our Discovery Assays. These assays provide cost-effective solutions tailored to various research needs, allowing scientists to uncover critical targets and explore complex immune responses. Our experts are available to assist with designing customized solutions to meet your specific research requirements.

Whether you are a clinician managing Long COVID patients or a researcher exploring its complex biology, Eve Technologies provides the tools and expertise to support your work. Trust our CLIA-certified laboratory for high-quality, reliable diagnostic solutions.

The Path Forward

Effective diagnosis and management of Long COVID are crucial for improving patient outcomes and advancing research. Eve Technologies’ CLIA certified Panel provides a powerful tool for investigating the biomarkers associated with this complex condition. For more information or to order our panel, please visit Patient Diagnostics or the Long Covid Vascular Health panel page. Together, we can enhance our understanding of yjis syndrome and support effective patient care.

References:

1. Klein, J., Wood, J., Jaycox, J. R., Dhodapkar, R. M., Lu, P., Gehlhausen, J. R., Tabachnikova, A., Greene, K., Tabacof, L., Malik, A. A., Silva Monteiro, V., Silva, J., Kamath, K., Zhang, M., Dhal, A., Ott, I. M., Valle, G., Peña-Hernández, M., Mao, T., Bhattacharjee, B., Takahashi, T., Lucas, C., Song, E., McCarthy, D., … & Iwasaki, A. (2023). Distinguishing features of long COVID identified through immune profiling. Nature, 623(1), 139-148
2. Madeeva, D. V., Christian, J., Goshua, G., Chun, H. J., Lee, A. I., & Pine, A. B. (2020). VWF/ADAMTS13 ratios are potential markers of immunothrombotic complications in patients with COVID-19: A cross-sectional study. Blood, 136(Supplement 1), 34-35.
3. Madeeva, D.V., Borges, K., Shallow, M., Juthani, P.V., Wang, S.Y., Gupta, A., Chun, H.J., Lee, A.I. and Pine, A.B., 2021. Proteomic profiles in patients with thrombosis due to COVID-19 are distinct from non-COVID-19 thrombosis. Blood, 138(Supplement 1), p.777.
4. Grady, C. B., Bhattacharjee, B., Silva, J., Jaycox, J., Lee, L. W., Monteiro, V. S., Sawano, M., Massey, D., Caraballo, C., Gehlhausen, J. R., Tabachnikova, A., Mao, T., Lucas, C., Peña-Hernandez, M. A., Xu, L., Tzeng, T. J., Takahashi, T., Herrin, J., Berrent Güthe, D., Akrami, A., Assaf, G., Davis, H., Harris, K., McCorkell, L., Schulz, W. L., Griffin, D., Wei, H., Ring, A. M., Guan, L., Dela Cruz, C., Iwasaki, A., & Krumholz, H. M. (2024). Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID [Preprint]. medRxiv.